Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.

Do analysts recommend HALO or EXEL?

Halozyme Therapeutics presently has a consensus target price of $54.78, suggesting a potential upside of 60.36%. Exelixis has a consensus target price of $25.33, suggesting a potential upside of 30.92%. Given Halozyme Therapeutics' higher possible upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Which has more risk and volatility, HALO or EXEL?

Halozyme Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Which has stronger earnings & valuation, HALO or EXEL?

Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$660.12 million	6.81	$202.13 million	$1.31	26.08
Exelixis	$1.61 billion	3.91	$182.28 million	$0.48	40.31

Is HALO or EXEL more profitable?

Halozyme Therapeutics has a net margin of 25.76% compared to Exelixis' net margin of 9.24%. Halozyme Therapeutics' return on equity of 184.32% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	25.76%	184.32%	16.05%
Exelixis	9.24%	6.20%	5.10%

Does the MarketBeat Community prefer HALO or EXEL?

Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 68.99% of users gave Halozyme Therapeutics an outperform vote while only 68.62% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Halozyme Therapeutics	Outperform Votes 476 68.99%	Underperform Votes 214 31.01%
Exelixis	Outperform Votes 551 68.62%	Underperform Votes 252 31.38%

Does the media prefer HALO or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Exelixis' average media sentiment score of 1.01 beat Halozyme Therapeutics' score of 0.34 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in HALO or EXEL?

96.3% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 84.7% of Exelixis shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Exelixis on 10 of the 17 factors compared between the two stocks.